Aspirin at 320 mg increases fibrin network permeability in patients with type 1 diabetes
FRIDAY, Dec. 16 (HealthDay News) -- Treatment with high-dose (320 mg), but not low-dose (75 mg), aspirin increases fibrin network permeability in patients with type 1 diabetes, according to a study published online Dec. 6 in Diabetes Care.
Sara Tehrani, M.D., from the Karolinska Institutet in Stockholm, Sweden, and colleagues investigated the effects of low- and high-dose aspirin treatment on fibrin network formation in patients with type 1 diabetes, and the association between these treatment effects and glycemic control. Forty-eight patients, 24 each with good and poor glycemic control (HbA1c <7.4 and >8.4 percent, respectively), were randomized to receive 75 or 320 mg/day aspirin in a crossover pattern during four weeks. The treatment periods were separated by a four-week washout period. The permeability coefficient (Ks) was determined to assess the plasma fibrin network.
The investigators found that the fibrin network permeability (Ks) was not affected by treatment with 75 mg aspirin, but that treatment with 320 mg of aspirin significantly increased Ks. There was a significant treatment effect for a dose of 320 mg versus a dose of 75 mg aspirin. In patients receiving high-dose aspirin, the increase in Ks was significant for those with poor glycemic control, while there was a trend toward significance for those with good glycemic control (P = 0.02 and 0.06, respectively).
"Treatment with high-dose aspirin (320 mg) is required to increase fibrin network permeability in patients with type 1 diabetes. The observed lack of effect with low-dose aspirin may contribute to aspirin treatment failure in diabetes," the authors write.
Abstract
Full Text (subscription or payment may be required)